Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)
This grant supports investigator-initiated clinical trials to reduce cancer burden through early detection, prevention, and survivorship improvements.
Browse similar grants
Funder: National Institutes of Health
Due Dates: November 5, 2026 (Renewal/resubmission/revision) | January 7, 2027 (Current closing date)
Funding Amounts: No budget limit; requests must reflect project needs; maximum project period of 5 years
Summary: Supports investigator-initiated clinical trials to reduce cancer burden through prevention, screening, early detection, healthcare delivery, survivorship, and quality-of-life improvements.
Key Information: Clinical trials are required; trials studying cancer diagnosis or oncologic therapy in patients are not supported.
Description
The National Cancer Institute (NCI) supports investigator-initiated Phase 0–IV clinical trials through this R01 program. Projects should align with the Division of Cancer Prevention or the Division of Cancer Control and Population Sciences and have the potential to improve clinical practice or public health. Relevant work includes cancer prevention and interception, screening, early detection, behavioral interventions, susceptibility-related interventions, implementation science, healthcare delivery, survivorship, supportive and palliative care, and quality of life.
Trials may include correlative laboratory or imaging studies and other trial-related endpoints, and may be combined with other research aims. This opportunity is not intended for observational studies. Phase III support is limited to public health, healthcare delivery, psychosocial, behavioral, environmental, policy, health-system, implementation, and related cancer prevention or control interventions that can be completed within the grant cycle.
